Markus Schlaich

2 months ago | mja.com.au | Aletta E Schutte |Markus Schlaich

Med J Aust 2025; 222 (2): 104-105.

Jun 23, 2023 | gisweb.vwd.com | Markus Schlaich |A Trustee

Nachrichtendetail 23.06.2023 17:50:04 - GNW-Adhoc: New Phase 3 data with aprocitentan to be presented at the European Society of Hypertension Annual Meeting 202 ^Allschwil, Switzerland - June 23, 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia's investigational dual endothelin receptor antagonist evaluating the treatment of patients with resistant hypertension, will be presented as an oral presentation by Prof. Markus Schlaich, MD, at the European...

Apr 20, 2023 | thelancet.com | Markus Schlaich |Marc Bellet |Michael Weber |George Bakris

We thank Donald E Kohan and Hiddo J L Heerspink for their interest in the PRECISION study and their comments regarding the potential for fluid retention and heart failure associated with endothelin receptor antagonists. Indeed, as described in publications from the past few years,1Schlaich MP Bellet M Weber MA et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.